Today
July 25, 2026Dilution Risk
4Last 7DListing Risk
37Last 30DEarnings
9Last 7DInsider / Ownership
3Last 14DDividends
1Last 30DFDA / Clinical
7Last 30DBGLN/A+0.00%
Legal Risk
Blue Gold Provides Update on Cayman Islands Court Ruling in Shareholder Litigation
Cayman court kept injunction blocking Blue Gold's EGM and Article amendments, extending litigation uncertainty.
bearishImpact 62
SIEBN/A+0.00%
Earnings
Siebert Reports First Quarter 2026 Financial Results
Siebert reports Q1 revenue $23.5M; stock loan and advisory growth, but net loss $2.0M.
neutralImpact 60
LGIHN/A+0.00%
Product Update
LGI Homes Opens New Community Within Los Lunas’ Expanding Los Senderos Development
LGI Homes opens a new Los Lunas community, expanding local inventory and early buyer interest.
bullishImpact 55
NXXTN/A+0.00%
Earnings
NextNRG Reports First Quarter 2026 Financial Results
NextNRG Q1 revenue +29% YoY and gross profit tripled, yet net loss widened and cash is low.
neutralImpact 60
NXXTN/A+0.00%
Earnings
NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET
NextNRG schedules Q1 2026 earnings call for May 18, 2026 at 9:00 a.m. ET.
neutralImpact 60
MARAN/A+0.00%
Strategic Transaction
MARA Announces Expiration and Results of the Consent Solicitation for the 8.750% Senior Secured Notes due 2032 of Long Ridge Energy LLC
MARA won majority consents to amend Long Ridge notes, enabling its planned acquisition pending approvals.
bullishImpact 78
SKEN/A+0.00%
Earnings
Skeena Gold & Silver Reports Q1 2026 Financial Results
Skeena filed Q1 2026 interim results; Eskay Creek construction continues toward Q2 2027 production.
bullishImpact 55
AGPUN/A+0.00%
Earnings
Axe Compute Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
Axe Compute signed a $260M 36-month GPU contract and began compute revenue, targeting Q3 2026 deployment.
bullishImpact 78
REGNN/A+0.00%
FDA / Clinical
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
Regeneron's Phase 3 fianlimab plus cemiplimab missed its PFS primary endpoint versus pembrolizumab, though high-dose showed numeric benefit.
bearishImpact 65
RIOFFN/A+0.00%
Earnings
Rio2 Reports First Quarter 2026 Financial Results and Operations Update
Rio2 posts Q1 production, Fenix ramp-up issues, Condestable adds cash flow, cash strengthens to $93.1M.
neutralImpact 62
NVTN/A+0.00%
Dividends
nVent Announces Quarterly Cash Dividend
nVent to pay a $0.21 quarterly cash dividend on August 7, 2026, record date July 24, 2026.
neutralImpact 55
NVTN/A+0.00%
Dilution Risk
nVent Announces Share Repurchase Authorization
nVent approved a $500 million, three-year share repurchase program effective July 23, 2026.
bullishImpact 68